Published 3 hours ago • loading... • Updated 2 hours ago

Lung Cancer, with New Disease Combination Under Control Longer

Summary by Rec News | Lontani Dal Mainstream

The phase 3 study Saffron, presented at the Madrid Esmo 2026 Congress, showed positive results for the combination of osimertinib and savolitinib in non-small cell lung cancer with Egfr mutation and Met alterations after progression with osimertinib. The combination of osimertinib and savolitinib reduced [...] The article Cancer lung, with new disease combination under control longer comes from Rec News.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

7 Articles

Quotidiano Nazionale

Lung Cancer, a New Option After the Progression of the Disease

The Saffron study, presented at Esmo 2026, “opens up new perspectives for some patients with lung cancer characterized by a mutation in the Egfr gene,” which may promote the growth of cancer cells. “The study involved patients whose disease had progressed despite treatment with osimertinib. The addition of savolitinib, a drug that acts against Met' — another gene that, when particularly active, can promote resistance to therapies — “has improved…

2 hours ago·Bologna, Italy

Read Full Article

CinqueColonne.it

Lung Cancer, with New Disease Combination Under Control Longer - Five Columns Magazine

The phase 3 study Saffron, presented at Madrid's Esmo 2026 congress, showed positive results for the combination of osimertinib and savolitinib in non-small cell lung cancer with Egfr mutation and Met alterations after progression with osimertinib. The combination of osimertinib and savolitinib reduced... Read more Lung cancer, with new disease combination under control longer comes from Five Columns Magazine.

3 hours ago

Read Full Article